65% had not transitioned to secondary progressive
multiple sclerosis (SPMS); 38%, 18%, and 3% reached
EDSS 4, 6, and 8.
For all patients on GA therapy (the mITT cohort), ARRs declined from 1.18 ± 0.82 to 0.43 ± 0.58 per year; 54% had stable/improved EDSS scores; 75% had not transitioned to SPMS; 39%, 23%, and 5% reached EDSS 4, 6, and 8.